Adiponectin Polymorphisms, Insulin Resistance, and Pharmacokinetics in Obesity

Trial ID or NCT#

NCT01593397

Status

not recruiting iconNOT RECRUITING

Purpose

The primary objective of this study is to determine the influence of insulin resistance on drug metabolism and response in obese subjects. The investigators hypothesize that expression of adiponectin (a hormone secreted by fat tissue), and specific variants in the adiponectin gene can predict the insulin resistance and drug response among obese subjects.

Official Title

Adiponectin Polymorphisms, Insulin Resistance, and Pharmacokinetics in Obesity

Eligibility Criteria

Ages Eligible for Study: 18 Years to 70 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. - Inclusion criteria include patients of adult age - American Society of Anesthesiologists Class I, II, or III, and undergoing elective surgical procedures requiring general anesthesia - Body mass index greater than 35
Exclusion Criteria:
  1. - Patients with evidence of hepatic, renal, or cardiovascular dysfunction - History of difficult tracheal intubation, or adverse reaction to anesthesia shall be excluded from the study - Patients taking prescribed or over-the-counter anxiolytics, narcotics, or sleeping aids, will also be excluded

Contact us to find out if this trial is right for you.

Contact

Jerry Ingrande, M.D., M.S.
650-723-7377